Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms, Glandular and Epithelial
Conditions
Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus, Whooping Cough, Meningitis
Trial Timeline
Apr 1, 2006 → Apr 1, 2007
NCT ID
NCT00325130About Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™
Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™ is a phase 3 stage product being developed by Merck for Neoplasms, Glandular and Epithelial. The current trial status is completed. This product is registered under clinical trial identifier NCT00325130. Target conditions include Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00325130 | Phase 3 | Completed |
Competing Products
20 competing products in Neoplasms, Glandular and Epithelial
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AB0024 | Gilead Sciences | Phase 1 | 32 |
| TTI-237 | Pfizer | Phase 1 | 32 |
| 852A | Pfizer | Phase 1 | 32 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| IMC-3C5 | Eli Lilly | Phase 1 | 33 |
| LY3295668 | Eli Lilly | Phase 1/2 | 41 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Fulvestrant + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| enzastaurin | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Darolutamide + LHRH agonist/antagonist | Eli Lilly | Phase 1 | 33 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 77 |
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 52 |
| LY4337713 | Eli Lilly | Phase 1 | 33 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant | Eli Lilly | Phase 3 | 77 |
| VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg | Vincerx Pharma | Phase 1 | 25 |
| VIP236 (Q3W) + VIP236 (Q2W) | Vincerx Pharma | Phase 1 | 25 |
| GEMZAR + ALIMTA | Eli Lilly | Phase 3 | 77 |